• Date: March 13, 2018

Founded at the Bellvitge Biomedical Research Institute (IDIBELL), ADmit Therapeutics is aiming to develop a diagnostic test to detect Alzheimer's disease in its very early stages.

It is the fifth spin-off that has resulted from the CaixaImpulse programme, in this case from the Kit for early Alzheimer's detection project from 2015, led by Marta Barrachina. Barrachina is the general director of the new company, and is joined by Ramón Reñé and Jordi Gascón as medical advisory board.

The in vitro diagnostic test developed by ADmit Therapeutics determines whether certain mitochondrial biomarkers are present in the blood. These biomarkers can indicate signs of the disease before the brain starts producing the protein aggregates that characterise Alzheimer's. Early diagnosis would allow those affected to start receiving the treatments available to slow down the progress of the disease, as there are still no treatments to reverse it. The company is seeking private investors as a step towards CE certification.

More programme highlights

September 12, 2018

Pitch Day for CaixaImpulse 2017 projects

On 6 September, CaixaForum Barcelona hosted a Pitch Day for the projects that took part in the CaixaImpulse 2017.

September 07, 2018

CaixaImpulse guides 20 biomedical projects to take the step from the laboratory to the market

A diagnostic kit for septicaemia and a medical device to reduce hospital-acquired infections are some examples of the projects featured in the 2018 programme.

August 30, 2018

CaixaImpulse 2018 kicks off with the Immersion Week

From 3-7 September, CaixaImpulse will host the first of four weeks of training available to this year’s participants.